Clinical Trial

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.
Protocol Amendment History 2 changes
notable Trial sites expanded: 66 -> 78 locations 2026-07-15
critical Recruitment opened 2026-04-21
Trial Details
NCT Number NCT07416474
Lead Sponsor RemeGen Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 574 participants
Start Date 2026-04-03
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14